Comprehensive Metabolic Panel Testing Market Expected to Reach $16.1 Billion by 2032

According to a new report published by Allied Market Research, titled, “Comprehensive Metabolic Panel Testing Market," The comprehensive metabolic panel testing market was valued at $10.1 billion in 2022, and is estimated to reach $16.1 billion by 2032, growing at a CAGR of 4.8% from 2023 to 2032. On the basis of test type, the others segment is expected to register the highest CAGR of 5.8% during the forecast period. In addition, Asia-Pacific is expected to register the highest CAGR of 5.9% during the forecast period.

A complete metabolic panel (CMP) is a blood check that offers a comprehensive assessment of individual metabolic fitness. It typically includes a combination of blood assessments that measure numerous components which includes electrolytes, glucose, kidney feature, liver feature, and other metabolic signs.

The comprehensive metabolic panel testing market trends include an increase in incidence of chronic conditions, which includes diabetes, cardiovascular issues, and kidney diseases that drives the need for regular metabolic testing to monitor and manage those situations. In addition, the increase in trend towards point-of-care testing has contributed to the increase in the adoption of comprehensive metabolic panel testing. Point-of-care testing includes conducting diagnostic assessments near the affected person, often at the bedside or in outpatient settings, considering rapid consequences and immediate medical choice-making. This shift in testing technique addresses the need for quicker and more convenient healthcare answers. In CMP testing, this trend is in particular impactful as it enables healthcare experts to rapidly check a patient's metabolic health without the need for extensive laboratory processing which is to drive the comprehensive metabolic panel testing market growth.

Furthermore, the focus on preventive health has played an important role in escalating the growth of comprehensive metabolic panel testing market. Growing interest in preventive health, people prefer to perform periodic health checks to identify health problems at an early stage. The CMP test featuring a wide spectrum of metabolic markers like glucose levels, kidney function and liver function is critical in preventive healthcare that boosts comprehensive metabolic panel testing industry growth.  

In contrast, the costs related to lab equipment and lack of highly skilled personnel are the factors which make the widespread acceptance of comprehensive metabolic testing difficult and restricts the market growth. On the other hand, the rise in demand for point-of-care testing is considered an important comprehensive metabolic panel testing market opportunity for market growth. The convenience, speed, and accessibility offered by POCT align with the evolving healthcare landscape, where decentralized diagnostic services play a crucial role.

The comprehensive metabolic panel testing market analysis is segmented on the basis of test type, disease indication, end user, and region. By test type, the market is classified into proteins, electrolytes, kidney tests, liver test, and others. The kidney tests segment dominated the market share in 2022 owing to increase in incidence of kidney-associated disorders, such as chronic kidney disease, has heightened the demand for kidney characteristic tests which necessitates CMP testing to check early symptoms of renal impairment.

However, the others segment is expected to register the highest CAGR during the comprehensive metabolic panel testing market forecast period. This is attributed to rise in incidence of diabetes and metabolic disorders globally has intensified the demand for glucose tracking, making it a pivotal aspect of the CMP. In addition, advancements in testing technologies further contribute to the segment growth. Continuous innovation in diagnostic technologies enhances the accuracy, speed, and efficiency of these tests, making them more accessible and reliable for routine health assessments which is expected to fuel segment growth.

By disease indication, the comprehensive metabolic panel testing industry is classified into kidney diseases, liver diseases, diabetes, and others. The kidney diseases segment dominated the market share in 2022. This is attributed to the increasing cases of kidney diseases and the awareness of early screening further stimulates the need for the CMP test. However, the diabetes segment is expected to register the highest CAGR during the forecast period. This is attributed to an increase in the number of diabetes cases and the expanding demand for preventive management and early detection of this condition.

By end user, it is segregated into hospitals, diagnostic laboratories, and others. The diagnostic laboratories segment dominated the comprehensive metabolic panel testing market share in 2022. This is attributed to the essential role these facilities play in delivering accurate and comprehensive metabolic testing services. However, the others segment is expected to register the highest CAGR during the forecast period. This is attributed to an increase in demand for decentralized, rapid, and on-the-spot diagnostic testing as they offer speed, accessibility, and efficiency in delivering comprehensive diagnostic information.

On the basis of region, North America accounted for largest comprehensive metabolic panel testing market size in 2022 and is expected to remain dominant during the forecast period, owing to advanced healthcare infrastructure, rise in technological advancements, a rise in prevalence of chronic diseases, and well-established healthcare practices. However, Asia-Pacific is anticipated to witness notable growth, owing to rapid economic development and urbanization, which has led to improvements in healthcare infrastructure and increased accessibility to healthcare services. In addition, rising incidence of lifestyle-related diseases, including diabetes and cardiovascular disorders, is a significant driver for increased metabolic testing in the Asia-Pacific region.

Key Findings of the Study    

• On the basis of test type, the kidney tests segment dominated the comprehensive metabolic panel testing market size in terms of revenue in 2022. However, the other segment is expected to register the highest CAGR during the forecast period. 

• On the basis of disease indication, the kidney diseases segment dominated the market in terms of revenue in 2022. However, the diabetes segment is expected to register the highest CAGR during the forecast period. 

• On the basis of end user, the diagnostic laboratories segment dominated the market in terms of revenue in 2022. However, the others segment is expected to register the highest CAGR during the forecast period. 

• On the basis of region, North America dominated the comprehensive metabolic panel testing market share in terms of revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.